RxDoctor Payments Data

Kent Haggard, MD

Urology · Independence, MONPI 1225069032

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,937 of the $8,762 with a category attached, or 67.8%. It is spread thinly across 43 manufacturers, the largest accounting for just 19.8%. Reporting peaked in 2020 at $2,119 and has fallen 59.1% since, to $866 in 2025.

$8,762in general payments, 2019–2025

Across 302 payments — averaging $29.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Caldera Medical, Inc$2K
  • Astellas Pharma US Inc$1K
  • Teleflex LLC$1K
  • AbbVie$449
  • Johnson & Johnson$380
  • Sumitomo Pharma America, Inc.$319
  • plus $3K from 37 others

What the payments were for

  • Consulting fees$1,60018%
  • Travel & lodging$6477%
  • Food & beverage$5,93768%
  • Education$5787%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,762 in reported general payments places this provider in the 75th percentile of 250 urology providers in Missouri.

See all urology providers in Missouri

Medicare billing

Part B allowed, 2024
$240,926
Medicare patients
604
Services billed
9,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron163$113,497
MyrbetriqMirabegron103$71,708
Estradiol107$7,018
Trospium Chloride ErTrospium Chloride29$6,877
Tamsulosin Hcl598$5,969
Oxybutynin Chloride ErOxybutynin Chloride166$3,583
Trospium Chloride85$2,999
Finasteride206$2,079
Testosterone25$1,227
Silodosin35$1,131
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst76$1,050
Alfuzosin Hcl ErAlfuzosin Hcl40$899
Dutasteride20$822
Cefdinir36$444
Methenamine Hippurate18$423

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$319$113,497163 claims
Astellas Pharma US IncMyrbetriq$1,361$71,708103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 250 urology providers in Missouri.

Other urology in Independence

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →